{"id":712,"date":"2020-12-14T07:27:27","date_gmt":"2020-12-14T07:27:27","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=712"},"modified":"2020-12-14T07:27:27","modified_gmt":"2020-12-14T07:27:27","slug":"12-dec-2020-itolizumab-reduced-il%e2%80%906-level-and-patients-showed-pulmonary-improvement","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/12-dec-2020-itolizumab-reduced-il%e2%80%906-level-and-patients-showed-pulmonary-improvement\/","title":{"rendered":"(12 Dec 2020) Itolizumab-  reduced IL\u20106 level and patients showed pulmonary improvement"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab<\/p>\n<p class=\"\">https:\/\/doi.org\/10.1002\/cti2.1218<\/p>\n<p class=\"\">Seventy critical, severe or moderate patients were treated with itolizumab in 10 Cuban hospitals. Median age was 68, and 94% had comorbidities. After 72 h, most patients improved the PO2\/FiO2 ratio and reduced FiO2 requirements. Ventilation time was 8 days for critical and 1 day for severe cases. Ten patients had related adverse events while 3 subjects developed related serious events. In 30 patients, interleukin 6 decreased in individuals with high level and did not change in those with lower concentration. Fourteen-day lethality rate was 4% and 18% for moderate and severe patients, respectively. The proportion of moderate or severe patients with ventilation or death at day 14 was 9.8%. Time to treatment, neurological manifestations and biomarkers such as NLR were significantly associated with higher lethality. The opportune administration of itolizumab might interrupt the hyperinflammatory cascade and prevent COVID-19 morbidity and mortality.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab https:\/\/doi.org\/10.1002\/cti2.1218 Seventy critical, severe or moderate patients were treated with itolizumab in 10 Cuban hospitals. Median age was 68, and 94% had comorbidities. After 72 h, most patients improved the PO2\/FiO2&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/12-dec-2020-itolizumab-reduced-il%e2%80%906-level-and-patients-showed-pulmonary-improvement\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(12 Dec 2020) Itolizumab-  reduced IL\u20106 level and patients showed pulmonary improvement&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,78],"tags":[79],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/712"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=712"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/712\/revisions"}],"predecessor-version":[{"id":713,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/712\/revisions\/713"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}